If this is not your name, click here.
| | If this is not your name, click here. | | |
| | Contact Us | Order Now | Journals | Bookstore | Register a colleague | | |
| |  HIV Appears to Moderately Increase Mortality Risk Even in People With High CD4 Count NEW YORK -- July 15, 2010 -- New research published online first by The Lancet suggests that HIV may increase the risk of death in people who have not taken antiretroviral treatment (ART) and have CD4 count >350 cells/microlitre, but any such increase appears relatively modest. Because ART might reduce the risk of death in such patients, these findings support the need for continuing studies of the risks and benefits of starting ART at CD4 counts >350 cells/microlitre. The article is written by Rebecca Lodwick, MD, and Andrew Phillips, HIV Epidemiology and Biostatistics Group, University College London Medical School, London, United Kingdom, and colleagues. The study included data from 23 European and North American cohorts. Standardised mortality ratios (SMRs) were calculated, adjusted by age, sex, and year, and stratified by risk group. Data were included for patients aged 20 to 59 years who had at least 1 CD4 count >350 cells/microlitre while ART naive. Mortality for 4 risk groups was investigated -- men who have sex with men, heterosexual people, injecting drug users, and those at other or unknown risk. Data were analysed for 40,830 patients contributing 80,682 person-years of follow-up. Of 419 deaths, 401 were used in the SMR analysis: 100 men who have sex with men (SMR 1.30 -- or a 30% increased risk compared with the general population); 68 heterosexual people (SMR 2.94, close to 3 times increased risk); 203 injecting drug users (SMR -9.37, more than 9 times increased risk); and 30 in the other or unknown risk category (4.57). Compared with CD4 counts of 350 to 499 cells per/microlitre, death rate was 23% lower in patients with counts of 500 to 699 cells per/microlitre and 34% lower for counts of >=700 cells per/microlitre. "The increase in risk was substantial in injecting drug users and the heterosexual group but was small in men who have sex with men," the authors wrote. "This finding suggests that much of the raised risk in the former 2 risk groups probably results from confounding by socioeconomic and lifestyle factors rather than being an effect of HIV infection itself. The magnitude of the raised risk in the MSM group is more likely to reflect the effect of HIV itself." The authors said this is consistent with findings from other studies that show an increased risk of death in the siblings of people with HIV infection compared with the siblings of a control population without HIV infection, i.e, it is probably the social or other circumstances that the person finds themselves in that increases the risk of death, rather than the HIV infection itself. "These data suggest that HIV may increase the risk of death in people who have not taken ART and have CD4 count greater than 350 cells/microlitre, but any such increase appears relatively modest," the authors concluded. "Because ART might reduce the risk of death in such patients, these findings support the need for continuing studies of the risks and benefits of starting ART at CD4 counts greater than 350 cells per microlitre." In an accompanying commentary, Ingrid Bassett, MD, Massachusetts General Hospital, and Paul Sax, MD, Brigham and Women's Hospital, and Harvard Medical School, Boston, Massachusetts, asked if similar results would be recorded in poorer settings, and said that the effect of untreated HIV infection on mortality with higher CD4 counts would probably be even higher due to higher levels of infectious diseases in such settings. "Lodwick and colleagues' study is one of the largest observational studies to analyse increased mortality in less-advanced HIV infection," they wrote. "Whether starting antiretrovirals at higher CD4 cell counts than are recommended in US and European guidelines reduces this risk remains unknown; at least 1 trial comparing immediate versus deferred antiretrovirals in these patients is in progress. With the results of this study probably years away, clinicians must aggressively screen, prevent, and treat risk factors for chronic diseases that seem to account for the residual excess mortality in early HIV-infection. Factors include tobacco use, intravenous drug use, hyperlipidaemia, hypertension, diabetes, obesity, and viral hepatitis. Even for those with relative immune competence, HIV infection remains a foe with many faces."
SOURCE: The Lancet
|
